Lv41
520 积分 2022-11-23 加入
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
1小时前
待确认
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer
11天前
已完结
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
11天前
已完结
PI3K and AKT Isoforms in Immunity
1年前
已完结
Safety and Efficacy of RAD001 (Everolimus) Administered Upon Relapse During or After Adjuvant Treatment in Post-menopausal Women With Hormone Receptor Positive, HER2/neu Negative Locally Advanced or Metastatic Breast Cancer (CRAD001JGR08 “MELPOMENI” study)
2年前
已关闭
皖公网安备34019202002308
